Insights

Here’s why the Patrys (ASX:PAB) share price is tumbling 16% today

Investors tend to keep a keen eye on clinical trial progress.
The post Here’s why the Patrys (ASX:PAB) share price is tumbling 16% today appeared first on The Motley Fool Australia. –

Patrys Limited (ASX: PAB) shares are tumbling in late morning trade. At the time of writing, the Patrys share price has slumped 16.33% following the company’s latest announcement.

Below we take a look at the ASX healthcare company’s update on its clinical trial preparation.

What update did Patrys report?

The Patrys share price is tanking after the company reported there were unanticipated delays in its PAT-DX1 clinical trial program.

Across a number of pre-clinical studies, PAT-DX1 has demonstrated significant ability to kill cancer cells.

In February, Patrys reported it had selected a “stable, high-yielding cell line suitable for the commercial production of clinical-grade PAT-DX1”. The company’s commercial contract manufacturer used this cell line to prepare the production and purification processes at its facility.

While the required materials were ordered 6 months in advance, the company reported that the COVID-19 pandemic has disrupted global reagent production and supply chains. Due to the proprietary nature of the reagents, Patrys said it is unable to source them from other suppliers.

Patrys now expects the engineering run for PAT-DX1 will be pushed back to the fourth quarter of this year. This will delay the start of its GMP toxicology studies to the first quarter of 2022, “pending the availability of GMP grade PAT-DX1”.

The company anticipates it will now submit a Human Research Ethics Application (HREA) for the phase 1 clinical trial in the second half of 2022.

Commenting on the delay, Patrys CEO James Campbell said it was obviously disappointing for the company and its loyal shareholders. He stressed that the delay is “based solely on global supply chains, not technical obstacles”.

Campbell added:

The recent data from ongoing pre-clinical studies has been extremely positive and has highlighted the many ways our deoxymabs may be able to improve the health of patients with a range of difficult to treat cancers.

We continue to work with our global suppliers to prepare for and initiate the first PAT-DX1 clinical trial in late 2022. In addition, we will continue to pursue a range of unique development opportunities for both PAT-DX1 and PAT-DX3.

Patrys share price snapshot

Despite today’s slide, the Patrys share price remains up more than 300% over the past 12 months, well outpacing the 28% gains posted by the All Ordinaries Index (ASX: XAO).

Year to date, the Patrys share price also continues to charge ahead, up 105% in 2021.

The post Here’s why the Patrys (ASX:PAB) share price is tumbling 16% today appeared first on The Motley Fool Australia.

Should you invest $1,000 in Patrys right now?

Before you consider Patrys, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Patrys wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

Here’s why the Patrys (ASX: PAB) share price is climbing 13% today

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!